SCHEMBL13729643

SCHEMBL13729643

CC(C)c1nc2cc(Cl)c(Cl)cc2s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLP1R P43220 4/20 0.38
SMN1; SMN2 Q16637 4/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
ALDH1A1 P00352 2/20 0.36
TP53 P04637 2/20 0.36
MAPT P10636 1/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NPSR1 Q6W5P4 1/20 0.35
SCN4A P35499 1/20 0.35
GAA P10253 2/20 0.34
MAPK1 P28482 1/20 0.34
LOXL2 Q9Y4K0 1/20 0.34
P2RX3 P56373 1/20 0.34
CCNT1 O60563 1/20 0.33
CDK9 P50750 1/20 0.33
AAK1 Q2M2I8 2/20 0.33
STING1 Q86WV6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2707208 0.86 NPC1 (0.45) SMN1; SMN2NPC1RAB9AALDH1A1TP53
SCHEMBL12205823 0.78 NPC1 (0.38) SMN1; SMN2NPC1RAB9AALDH1A1TP53
SCHEMBL86109 0.78 GAA (0.59) SMN1; SMN2NPC1RAB9AALDH1A1TP53
SCHEMBL2609448 0.78 NPC1 (0.51) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL15481036 0.78 SMN1; SMN2 (0.56) SMN1; SMN2NPC1RAB9ANPSR1GAA
SCHEMBL2756559 0.77 SMN1; SMN2 (0.61) SMN1; SMN2NPC1RAB9AALDH1A1TP53
SCHEMBL26438869 0.77 ACACB (0.41) SMN1; SMN2NPC1RAB9AALDH1A1TP53
SCHEMBL24466885 0.76 HSD17B10 (0.46) SMN1; SMN2NPC1RAB9AALDH1A1TP53
SCHEMBL12231965 0.74 GAA (0.44) SMN1; SMN2NPC1RAB9AALDH1A1TP53
SCHEMBL21422893 0.74 GAA (0.44) SMN1; SMN2NPC1RAB9AALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203705-A1 Spiro Compounds As NPY Y5 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203705-A1 Spiro Compounds As NPY Y5 Receptor Antagonists NPY4R, NPY1R, NPY5R GLP1R 48/4885SMN1; SMN2 3259/4885NPC1 730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.